{"version":3,"file":"ResearchStudyPhaseCodes.js","sources":["../../src/fhirValueSets/ResearchStudyPhaseCodes.ts"],"sourcesContent":["// <auto-generated/>\r\n// Contents of: hl7.fhir.r4.core version: 4.0.1\r\n// Minimum TypeScript Version: 3.7\r\n// FHIR ValueSet: http://hl7.org/fhir/ValueSet/research-study-phase|4.0.1\r\n\r\n/**\r\n * Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.\r\n */\r\nexport const ResearchStudyPhaseCodes = {\r\n  /**\r\n   * early-phase-1: Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0.\r\n   */\r\n  EarlyPhase1: \"early-phase-1\",\r\n  /**\r\n   * n-a: Trials without phases (for example, studies of devices or behavioral interventions).\r\n   */\r\n  NA: \"n-a\",\r\n  /**\r\n   * phase-1: Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.\r\n   */\r\n  Phase1: \"phase-1\",\r\n  /**\r\n   * phase-1-phase-2: Trials that are a combination of phases 1 and 2.\r\n   */\r\n  Phase1Phase2: \"phase-1-phase-2\",\r\n  /**\r\n   * phase-2: Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.\r\n   */\r\n  Phase2: \"phase-2\",\r\n  /**\r\n   * phase-2-phase-3: Trials that are a combination of phases 2 and 3.\r\n   */\r\n  Phase2Phase3: \"phase-2-phase-3\",\r\n  /**\r\n   * phase-3: Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.\r\n   */\r\n  Phase3: \"phase-3\",\r\n  /**\r\n   * phase-4: Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.\r\n   */\r\n  Phase4: \"phase-4\",\r\n} as const;\r\n\r\n/**\r\n * Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.\r\n */\r\nexport type ResearchStudyPhaseCodeType = typeof ResearchStudyPhaseCodes[keyof typeof ResearchStudyPhaseCodes];\r\n"],"names":[],"mappings":";;AAAA;AACA;AACA;AACA;AAEA;;AAEG;AACU,IAAA,uBAAuB,GAAG;AACrC;;AAEG;AACH,IAAA,WAAW,EAAE,eAAe;AAC5B;;AAEG;AACH,IAAA,EAAE,EAAE,KAAK;AACT;;AAEG;AACH,IAAA,MAAM,EAAE,SAAS;AACjB;;AAEG;AACH,IAAA,YAAY,EAAE,iBAAiB;AAC/B;;AAEG;AACH,IAAA,MAAM,EAAE,SAAS;AACjB;;AAEG;AACH,IAAA,YAAY,EAAE,iBAAiB;AAC/B;;AAEG;AACH,IAAA,MAAM,EAAE,SAAS;AACjB;;AAEG;AACH,IAAA,MAAM,EAAE,SAAS;;;;;"}